|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pathogenesis and clinical management of Helicobacter pylori gastric infection显示文摘Helicobacter pylori(H.pylori)is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide.However,its prevalence varies among different geographic areas,and is influenced by several factors.The infection can be acquired by means of oral-oral or fecal-oral transmission,and the pathogen possesses various mechanisms that improve its capacity of mobility,adherence and manipulation of the gastric microenvironment,making possible the colonization of an organ with a highly acidic lumen.In addition,H.pylori presents a large variety of virulence factors that improve its pathogenicity,of which we highlight cytotoxin associated antigen A,vacuolating cytotoxin,duodenal ulcer promoting gene A protein,outer inflammatory protein and gamma-glutamyl transpeptidase.The host immune system,mainly by means of a Th1-polarized response,also plays a crucial role in the infection course.Although most H.pylori-positive individuals remain asymptomatic,the infection predisposes the development of various clinical conditions as peptic ulcers,gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas.Invasive and non-invasive diagnostic methods,each of them with their related advantages and limitations,have been applied in H.pylori detection.Moreover,bacterial resistance to antimicrobial therapy is a major challenge in the treatment of this infection,and new therapy alternatives are being tested to improve H.pylori eradication.Last but not least,the development of effective vaccines against H.pylori infection have been the aim of several research studies. | Breno Bittencourt de Brito Filipe Ant?nio Fran?a da Silva Aline Silva Soares Vinícius Afonso Pereira Maria Luísa Cordeiro Santos Mariana Miranda Sampaio Pedro Henrique Moreira Neves Fabrício Freire de Melo | 2019 | World Journal of Gastroenterology2019，25，37： | 84 |
| 2 | Update on prevention and screening of cervical cancer显示文摘Cervical cancer is the third most common cause of cancer in women in the world. During the past few decades tremendous strides have been made toward decreasing the incidence and mortality of cervical cancer with the implementation of various prevention and screening strategies. The causative agent linked to cervical development and its precursors is the human papillomavirus(HPV). Prevention and screening measures for cervical cancer are paramount because the ability to identify and treat the illness at its premature stage often disrupts the process of neoplasia. Cervical carcinogenesis can be the result of infections from multiple high-risk HPV types that act synergistically. This imposes a level of complexity to identifying and vaccinating against the actual causative agent. Additionally, most HPV infections spontaneously clear. Therefore, screening strategies should optimally weigh the benefits and risks of screening to avoid the discovery and needless treatment of transient HPV infections. This article provides an update of the preventative and screening methodsfor cervical cancer, mainly HPV vaccination, screening with Pap smear cytology, and HPV testing. It also provides a discussion of the newest United States 2012 guidelines for cervical cancer screening, which changed the age to begin and end screening and lengthened the screening intervals. | Shaniqua L Mc Graw Jeanne M Ferrante | 2014 | World Journal of Clinical Oncology2014，5，4： | 17 |
| 3 | Persistence of hepatitis B vaccine immune protection and response to hepatitis B booster immunization显示文摘AbstractAIMToidentifythepersistenceofimmuneprotectionofChinamade,plasmaderivedhepatitisBvaccineafterinfancyimmunizationandt... | LI Hui 1, LI Rong Cheng 2, LIAO Su Su 1, YANG Jin Ye 2, ZENG Xian Jia 1 and WANG Shu Sheng 2 | 1998 | World Journal of Gastroenterology1998，4，6： | 15 |
| 4 | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines显示文摘SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain(RBD)and N-terminal domain(NTD).Here we report the humoral immune response to circulating SARS-CoV-2 variants,such as 501Y.V2(B.1.351),of the plasma and neutralizing antibodies(NAbs)elicited by CoronaVac(inactivated vaccine),ZF2001(RBD-subunit vaccine)and natural infection.Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents,near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination,with E484K being the dominant cause.VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants,and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions.In contrast,the 242–244 deletion(242–244Δ)would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite,indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs.Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo-and authentic 501Y.V2 variants,mainly caused by E484K/N501Y and 242–244Δ,with the effects being additive.Importantly,RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents,since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations.Moreover,an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration.Together,these results suggest that the deployment of RBD-vaccines,through a third-dose boost,may be ideal for combating SARS-CoV-2 variants when necessary,especially for those carrying mutations that disrupt the NTD supersite. | Yunlong Cao Ayijiang Yisimayi Yali Bai Weijin Huang Xiaofeng Li Zhiying Zhang Tianjiao Yuan Ran An Jing Wang Tianhe Xiao Shuo Du Wenping Ma Liyang Song Yongzheng Li Xiang Li Weiliang Song Jiajing Wu Shuo Liu Xuemei Li Yonghong Zhang Bin Su Xianghua Guo Yangyang Wei Chuanping Gao Nana Zhang Yifei Zhang Yang Dou Xiaoyu Xu Rui Shi Bai Lu Ronghua Jin Yingmin Ma Chengfeng Qin Youchun Wang Yingmei Feng Junyu Xiao Xiaoliang Sunney Xie | 2021 | Cell Research2021，31，7： | 12 |
| 5 | New targeted therapies in pancreatic cancer显示文摘Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does not exceed 6 mo, likely due to natural resistance to gemcitabine. Therefore, it is hoped that more favorable results can be obtained by using guided immunotherapy against molecular targets. This review summarizes the new leading targeted therapies in pancreatic cancers, focusing on passive and specific immunotherapies. Passive immunotherapy may have a role for treatment in combination with radiochemotherapy, which otherwise destroys the immune system along with tumor cells. It includes mainly therapies targeting against kinases, including epidermal growth factor receptor, Ras/Raf/mitogenactivated protein kinase cascade, human epidermal growth factor receptor 2, insulin growth factor-1 receptor, phosphoinositide 3-kinase/Akt/m TOR and hepatocyte growth factor receptor. Therapies against DNA repair genes, histone deacetylases, micro RNA, and pancreatic tumor tissue stromal elements(stromal extracellular matric and stromal pathways) are also discussed. Specific immunotherapies, such as vaccines(whole cell recombinant, peptide, and dendritic cell vaccines), adoptive cell therapy and immunotherapy targeting tumor stem cells, have the role of activating antitumor immune responses. In the future, treatments will likely include personalized medicine, tailored for numerous molecular therapeutic targets of multiple pathogenetic pathways. | Andrada Seicean Livia Petrusel Radu Seicean | 2015 | World Journal of Gastroenterology2015，21，20： | 12 |
| 6 | Immunotherapeutic approaches in biliary tract carcinoma:Current status and emerging strategies显示文摘For biliary tract carcinoma(BTC),complete surgical resection of tumor is only feasible in a minority of patients,and the treatment options for patients with unresectable or metastatic disease are limited.Advances in cancer immunology have led to identification of tumor-infiltrating immune cells as indicators of prognosis and response to treatment in BTC.This has also facilitated development of immunotherapy that focuses on enhancing the immune system against biliary tumors.This includes peptide- and dendritic cell-based vaccines that stimulate in-vivo immune responses against tumorspecific antigens.Adoptive immunotherapy,which entails the ex-vivo expansion of tumor-infiltrating immune cells for subsequent reintroduction,and cytokinebased therapies have been developed in BTC.Clinical studies indicate that this type of therapy is generally well tolerated.Combination therapy with dendritic cell-based vaccines and adoptive immunotherapy has shown particularly good potential.Emerging strategies through discovery of novel antigen targets and by reversal of tumor-associated immunosuppression are expected to improve the efficacy of immunotherapy in BTC.Collaborative efforts by integration of targeted immunotherapeutics with molecular profiling of biliary tumor will hopefully make a positive impact on advancing towards the goal of developing precision treatment of patients with this highly lethal disease. | Eric I Marks Nelson S Yee | 2015 | World Journal of Gastrointestinal Oncology2015，7，11： | 11 |
| 7 | Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens显示文摘Therapeutic options for the treatment of colorectal cancer(CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hypermutated tumors suggests a permanent role of immune therapy in the clinical management of CRC. Substantial improvement in treatment outcome could be achieved by development of efficient patient-individual CRC vaccination strategies. This mini-review summarizes the current knowledge on the two general classes of targets: tumor-associated antigens(TAAs) and tumorspecific antigens. TAAs like carcinoembryonic antigen and melanoma associated antigen are present in and shared by a subgroup of patients and a variety of clinical studies examined the efficacy of different TAA-derived peptide vaccines. Combinations of several TAAs as the next step and the development of personalized TAA-based peptide vaccines are discussed. Improvements of peptidebased vaccines achievable by adjuvants and immunestimulatory chemotherapeutics are highlighted. Finally, we sum up clinical studies using tumor-specific antigens-in CRC almost exclusively neoantigens-which revealed promising results; particularly no severe adverse events were reported so far. Critical progress for clinical outcomes can be expected by individualizing neoantigen-based peptide vaccines and combining them with immunestimulatory chemotherapeutics and immune checkpoint inhibitors. In light of these data and latest developments, truly personalized neoantigen-based peptide vaccines can be expected to fulfill modern precision medicine's requirements and will manifest as treatment pillar for routine clinical management of CRC. | Sandra Wagner Christina S Mullins Michael Linnebacher | 2018 | World Journal of Gastroenterology2018，24，48： | 10 |
| 8 | Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates显示文摘Dear Editor,Omicron(B.1.1.529),is a heavily mutated and highly contagious SARS-CoV-2 variant,which is currently causing large outbreaks in many countries.Protection provided by current vaccines is substantially reduced against Omicron.1,2 Moreover,many immunocompromised individuals cannot effectively be protected by vaccines.3 Hence,antiviral therapies will be essential to protect the most vulnerable individuals from severe COVID-19. | Denisa Bojkova Marek Widera Sandra Ciesek Mark N.Wass Martin Michaelis Jindrich Cinatl Jr | 2022 | Cell Research2022，32，3： | 10 |
| 9 | Long-term eficacy of plasma-derived hepatitis B vaccine among Chinese children:a 12-year folow-up study显示文摘INTRODUCTIONToevaluatelongtermeficacyofaplasmaderivedhepatitisBvaccineandprovideevidencefordecisionmakingonthevaccineboost... | LIAO Su Su 1, LI Rong Cheng 2, LI Hui 1, YANG Jin Ye 2, ZENG Xian Jia 1, GONG Jian 2, WANG Shu Sheng 2, LI Yan Ping 2 and ZHANG Kong Lai 1 | 1999 | World Journal of Gastroenterology1999，5，2： | 9 |
| 10 | Multi-epitope vaccines: a promising strategy against tumors and viral infections显示文摘Immune responses play a critical role in fighting tumors and viral infections.An antigenic epitope is a basic unit that elicits either a cellular or a humoral immune response.A multi-epitope vaccine composed of a series of or overlapping peptides is therefore an ideal approach for the prevention and treatment of tumors or viral infections.1,2,3,4,5 Although some multi-epitope vaccines have entered phase I clinical trials,for example,EMD640744 in patients with advanced solid tumors,6 designing efficacious multi-epitope vaccines remains a great challenge.An ideal multi-epitope vaccine should be designed to include epitopes that can elicit CTL,Th and B cells and induce effective responses against a targeted tumor or virus(Figure 1). | Lifang Zhang | 2018 | Cellular & Molecular Immunology2018，15，2： | 8 |
| 11 | COVID-19 mRNA vaccines显示文摘The ongoing COVID-19 pandemic and its unprecedented global societal and economic disruptive impact highlight the urgent need for safe and effective vaccines.Taking substantial advantages of versatility and rapid development,two m RNA vaccines against COVID-19 have completed late-stage clinical assessment at an unprecedented speed and reported positive results.In this review,we outline keynotes in m RNA vaccine development,discuss recently published data on COVID-19 m RNA vaccine candidates,focusing on those in clinical trials and analyze future potential challenges. | Qingrui Huang Jiawei Zeng Jinghua Yan | 2021 | Journal of Genetics and Genomics2021，48，2： | 7 |
| 12 | Human immunology and immunotherapy:main achievements and challenges显示文摘The immune system is a fascinating world of cells,soluble factors,interacting cells,and tissues,all of which are interconnected.The highly complex nature of the immune system makes it difficult to view it as a whole,but researchers are now trying to put all the pieces of the puzzle together to obtain a more complete picture.The development of new specialized equipment and immunological techniques,genetic approaches,animal models,and a long list of monoclonal antibodies,among many other factors,are improving our knowledge of this sophisticated system.The different types of cell subsets,soluble factors,membrane molecules,and cell functionalities are some aspects that we are starting to understand,together with their roles in health,aging,and illness.This knowledge is filling many of the gaps,and in some cases,it has led to changes in our previous assumptions;e.g.,adaptive immune cells were previously thought to be unique memory cells until trained innate immunity was observed,and several innate immune cells with features similar to those of cytokine-secreting T cells have been discovered.Moreover,we have improved our knowledge not only regarding immune-mediated illnesses and how the immune system works and interacts with other systems and components(such as the microbiome)but also in terms of ways to manipulate this system through immunotherapy.The development of different types of immunotherapies,including vaccines(prophylactic and therapeutic),and the use of pathogens,m onodonal antibodies,recombinant proteins,cytokines,and cellular immunotherapies,are changing the way in which we approach many diseases,especially cancer. | Jezabel Varade Susana Magadan Africa Gonzalez-Fernandez | 2021 | Cellular & Molecular Immunology2021，18，4： | 7 |
| 13 | H2 strain attenuated live hepatitis A vaccines:protective efficacy in a hepatitis A outbreak显示文摘AIM To investigate the protective efficacy ofH2 strain attenuated live hepatitis A vaccines(H2-strain vaccines)in hepatitis A(HA)outbreaks.METHODS With the permission of theirparents,5551 pre-school and grade 1-3 primaryschool children were inoculated with 1 dose(106.5TCID50)of H2-strain vaccines in anonrandomized,controlled trial conducted inFucheng County,Hebei Province in May 1997.Another 6485 children in the same grades andcompatible in gender and age were enrolled ascontrols.Epidemiological and serological surveywas conducted to evaluate the protectiveefficacy of the vaccines.ELISA was used todetect serum IgM anti-HAV.RESULTS HA outbreak started in early May1998,peaked in the middle of the same month,and lasted about 80 days.Overall 302 HA caseswere found,192(53.58%)were 5-9 years old.One vaccinee and 25 control cases were found tohave hepatitis A,which account for 0.28%(1/356)and 5.92%(25/422)of all vaccinees andcontrols in the 14 villages,respectively.The protective efficacy of vaccines was 95.27%(95% Cl:85.83%-104.72%).In subjects testedfor anti-HAV IgM from 13 villages,1(0.40%)overt and 11(4.06%)asymptomatic HAV caseswere found in 271 vaccinees,but 21(6.69%)ofovert and asymptomatic ones were found in 314controls.CONCLUSION H2 strain vaccines were excellent in preventing overt hepatitis A, but not so effective in preventing asymptomatic hepatitis A virus infection. A booster dose might be needed to get permanent reliable immunity. | Yu Liang Zhao Zong Da Meng Zhi Yi Xu Jun Jie Guo Shao Ai Chai Cheng Gang Duo Xuan Yi Wang Jin Feng Yao Hong Bin Liu Shun Xiang Qi Hui Bin Zhu | 2000 | World Journal of Gastroenterology2000，6，6： | 7 |
| 14 | Recent advances in heat shock protein-based cancer vaccines显示文摘BACKGROUND: Active immunotherapy has been successful in preventing many infectious diseases, and is being explored for its anti-tumor use. Purified antigens, peptides, gene-based systems and antigens contained in whole cells or cell lysates are used in specific active immunotherapy for cancer, known as cancer vaccines. Cancer vaccines do not directly kill tumor cells, but prime a specific humoral and/or cellular immune response against the tumor. Up to date, many kinds of cancer vaccines have been tested in the world and have shown their own advantages. Heat shock protein (HSP)-based cancer vaccine is one of the outstanding representatives. In this paper, we review recent advances in HSP-based cancer vaccines. DATA SOURCES: An English-language literature search was conducted using MEDLINE (1990-2005) on HSP, cancer vaccines and other related subjects. RESULTS: Several kinds of HSP-based cancer vaccines which have been explored worldwide, include tumor derived HSP-pepdde complex cancer vaccines, artificially reconstituted HSP-peptide complex cancer vaccines, HSPpeptide fusion protein cancer vaccines and HSP-based DNA cancer vaccines, etc. Many HSP-based cancer vaccines are being tested in clinical trials, and some are being tested in phase Ⅲ clinical trials at present. CONCLUSION: The available results in preclinical tests and clinical trials indicate that HSP-based cancer vaccines are promising in cancer therapy. | Hao-Hao Wang, Chen-Yu Mao, Li-Song Teng and Jiang Cao Department of Oncology Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China Clinical Research Institute, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，1： | 7 |
| 15 | Infectious laryngotracheitis virus in chickens显示文摘Infectious laryngotracheitis(ILT) is an important respiratory disease of chickens and annually causes significant economic losses in the poultry industry worldwide. ILT virus(ILTV) belongs to alphaherpesvirinae and the Gallid herpesvirus 1 species. The transmission of ILTV is via respiratory and ocular routes. Clinical and post-mortem signs of ILT can be separated into two forms according to its virulence. The characteristic of the severe form is bloody mucus in the trachea with high mortality. The mild form causes nasal discharge, conjunctivitis, and reduced weight gain and egg production. Conventional polymerase chain reaction(PCR), nested PCR, real-time PCR, and loop-mediated isothermal amplification were developed to detect ILTV samples from natural or experimentally infected birds. The PCR combined with restriction fragment length polymorphism(RFLP) can separate ILTVs into several genetic groups. These groups can separate vaccine from wild type field viruses. Vaccination is a common method to prevent ILT. However, field isolates and vaccine viruses can establish latent infected carriers. According to PCR-RFLP results, virulent field ILTVs can be derived from modified-live vaccines. Therefore, modified-live vaccine reversion provides a source for ILT outbreaks on chicken farms. Two recently licensed commercial recombinant ILT vaccines are also in use. Other recombinant and gene-deficient vaccine candidates are in the developmental stages. They offer additional hope for the control of this disease. However, in ILT endemic regions, improved biosecurity and management practices are critical for improved ILT control. | Shan-Chia Ou Joseph J Giambrone | 2012 | World Journal of Virology2012，1，5： | 6 |
| 16 | Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction显示文摘Since the early 1800s vaccines have saved numerous lives by preventing lethal infections.However,during the past two decades,there has been growing awareness of possible adverse events associated with vaccinations,cultivating heated debates and leading to significant fluctuations in vaccination rates.It is therefore pertinent for the scientific community to seriously address public concern of adverse effects of vaccines to regain public trust in these important medical interventions.Such adverse reactions to vaccines may be viewed as a result of the interaction between susceptibility of the vaccinated subject and various vaccine components.Among the implicated mechanisms for these reactions is molecular mimicry.Molecular mimicry refers to a significant similarity between certain pathogenic elements contained in the vaccine and specific human proteins.This similarity may lead to immune crossreactivity,wherein the reaction of the immune system towards the pathogenic antigens may harm the similar human proteins,essentially causing autoimmune disease.In this review,we address the concept of molecular mimicry and its application in explaining post vaccination autoimmune phenomena.We further review the principal examples of the influenza,hepatitis B,and human papilloma virus vaccines,all suspected to induce autoimmunity via molecular mimicry.Finally,we refer to possible implications on the potential future development of better,safer vaccines. | Yahel Segal Yehuda Shoenfeld | 2018 | Cellular & Molecular Immunology2018，15，6： | 6 |
| 17 | Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines显示文摘Seasonal influenza epidemics and influenza pandemics caused by influenza A virus(IAV)has resulted in millions of deaths in the world.The development of anti-IAV vaccines and therapeutics is urgently needed for prevention and treatment of IAV infection and for controlling future influenza pandemics.Hemagglutinin(HA)of IAV plays a critical role in viral binding,fusion and entry,and contains the major neutralizing epitopes.Therefore,HA is an attractive target for developing anti-IAV drugs and vaccines.Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines. | Shibo Jiang Runming Li Lanying Du Shuwen Liu | 2010 | Protein & Cell2010，1，4： | 5 |
| 18 | Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice显示文摘The novel coronavirus SARS-CoV-2 has infected more than 104 million individuals and resulted in more than 2.2 million deaths worldwide as of February 7,2021(https://covid19.who.int).The COVID-19 pandemic highlights the need for safe and effective vaccines against SARS-CoV-2 infection. | Shihui Sun Lei He Zhongpeng Zhao Hongjing Gu Xin Fang Tiecheng Wang Xiaolan Yang Shaolong Chen Yongqiang Deng Jiangfan Li Jian Zhao Liang Li Xinwang Li Peng He Ge Li Hao Li Yuee Zhao Chunrun Gao Xiaoling Lang Xin Wang Guoqiang Fei Yan Li Shusheng Geng Yuwei Gao Wenjin Wei Zhongyu Hu Gencheng Han Yansong Sun | 2021 | Cellular & Molecular Immunology2021，18，4： | 5 |
| 19 | HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection显示文摘BACKGROUND: As the host immunity is diminished in patients with chronic hepatitis B (CHB), different approaches have been used to up-regulate their immune responses to produce therapeutic effects. But, cytokines, growth factors and polyclonal immune modulators could not exhibit sufficient therapeutic effects in these patients. Immune therapy with HBV-related antigens (vaccine therapy) has been used in CHB patients. But there is a paucity of information about the design of HBV antigen-based immune therapy in these patients. DATA SOURCE: Preclinical and clinical studies on immune therapy with HBsAg-based vaccine, HBcAg and combination of HBsAg/HBcAg-based vaccines have been discussed. RESULTS: HBsAg-based prophylactic vaccine was used as an immune therapeutic agent in CHB patients; however, monotherapy with HBsAg-based immune therapy could not lead to sustained control of HBV replication and/or liver damages. HBsAg-based vaccine was used as a combination therapy with cytokines, growth factors, and antiviral drugs. HBsAg-based vaccine was also used for cell-based therapy. However, satisfactory therapeutic effects of HBsAg-based vaccine could not be documented in CHB patients. In the mean time, evidences have supported that HBcAg-specific immunity is endowed with antiviral and liver protecting capacities in CHB patients. Recent data concentrate on the clinical use of combined HBsAg- and HBcAg-based vaccines in CHB patients.CONCLUSION: Antigen-based immune therapy with HBV- related antigens may be an alternative method for the treatment of CHB patients but proper designs of antigens, types of adjuvants, dose of vaccinations, and routes of administration need further analyses for the development of an effective regimen of immune therapy against HBV. | Sheikh Mohammad Fazle Akbar Mamun Al-Mahtab Mohammad Helal Uddin Md. Sakirul Islam Khan | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，4： | 5 |
| 20 | Immunological effects of a 10-μg dose of domestic hepatitis B vaccine in adults显示文摘Objective:To evaluate the immunological effects of three types of domestic 10-μg/dose hepatitis B vaccines in adults compared with a foreign vaccine, and to provide scientific evidence in support of adult hepatitis B vaccination. Methods:Adults from five counties (Deqing, Changxing, Nanxun, Wuxing, Anji) in Huzhou City, Shaoxing County and Tongxiang County, Zhejiang Province, China were selected. Blood samples were taken to assess serum HBsAg, anti-HBs, and anti-HBc using a chemiluminescence immunoassay. Adults, aged 16 to 49 years and who were anti-HBs negative at baseline, received hepatitis B immunizations at 0, 1, and 6 months. Anti-HBs levels were assessed one month after the third and final vaccination. Results:A total of 1 872 adults were immunized and the average positive rate was 89.5%. Four types of hepatitis B vaccine were used, including three from Chinese companies (Shenzhen Kangtai, Dalian High-Tech, and North China Pharmaceutical) and one from a UK company (GlaxoS-mithKline). Their seroconversion rates were 81.67%, 95.05%, 89.64%, and 86.81%, respectively. There was a significant difference between the anti-HBs positive conversion rates of the four types (P<0.005) but the seroconversion rates among the different vaccines were not significantly different (χ 2 =2.123, P=0.145). The average anti-HBs geometric mean titers (GMTs) of non-immune adults immunized with each of the four vaccines were 177.28, 473.23, 246.13, and 332.20 mIU/ml, respectively. There were no sta- tistically significant differences in the GMTs between the three types of domestic vaccine and the foreign vaccine (t= 1.575, P=0.116). Conclusions:Domestic recombinant hepatitis B vaccines can achieve immunization effects comparable to those of a foreign vaccine. | Jing-jing REN Xue-wei DAI Zheng-gang JIANG Ling-zhi SHEN Yong-di CHEN Qian LI Wen REN Ying LIU Jun YAO Lan-juan LI | 2012 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2012，13，11： | 5 |
您所在的机构暂未开通此部分的功能，请联系管理员